Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.34 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | NPR1 | P16066 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863617 | 0.88 | ALDH1A1 (0.35) | CDK5CDK5R1MAPK1KDM4EALDH1A1 | |
| SCHEMBL3714054 | 0.85 | KDM4E (0.37) | CDK5CDK5R1KDM4EALDH1A1RXFP1 | |
| SCHEMBL3714056 | 0.85 | KDM4E (0.37) | CDK5CDK5R1KDM4EALDH1A1RXFP1 | |
| SCHEMBL865348 | 0.81 | KDM4E (0.45) | CDK5CDK5R1MAPK1KDM4EALDH1A1 | |
| SCHEMBL3711295 | 0.79 | ALDH1A1 (0.39) | CDK5CDK5R1MAPK1KDM4EALDH1A1 | |
| SCHEMBL15184778 | 0.79 | HTR7 (0.39) | KDM4EALDH1A1RXFP1 | |
| SCHEMBL864178 | 0.79 | HTR7 (0.39) | KDM4EALDH1A1RXFP1 | |
| SCHEMBL3711291 | 0.76 | ALDH1A1 (0.35) | CDK5CDK5R1KDM4EALDH1A1RXFP1 | |
| SCHEMBL716685 | 0.76 | L3MBTL1 (0.34) | — | |
| SCHEMBL14482160 | 0.76 | MEN1 (0.35) | KDM4EALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | CDK5 92/4885CDK5R1 254/4885MAPK1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.